Marlana Orloff1. 1. Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Abstract
BACKGROUND: Uveal melanoma (UM) is a rare subtype of melanoma that generally has a poor prognosis once it has metastasized. Clinical trials evaluating immune checkpoint inhibitors (ICIs) in UM have demonstrated response rates lower than those seen in cutaneous melanoma. Despite lower efficacy demonstrated in initial ICI studies, there are a number of ongoing clinical trials investigating novel immunotherapy approaches in UM. SUMMARY: This review aims to summarize important ongoing clinical trials investigating immunotherapeutic approaches in UM and previous trials that have evaluated a number of immunologic interventions. A thorough clinical trial investigation was conducted through clinicaltrials.gov using the disease search terms "uveal melanoma" and "ocular melanoma," excluding non-immunotherapy-related trials. Here, we report on ICI, vaccine, adoptive T cells, and combination immunotherapy trials in UM. KEY MESSAGES: There is an increasing effort in the search for new, effective therapies for this difficult-to-treat disease, with immunotherapeutic approaches being of particular interest. Increasing knowledge of UM biology and development of new biomarkers will direct future drug development and trial design.
BACKGROUND: Uveal melanoma (UM) is a rare subtype of melanoma that generally has a poor prognosis once it has metastasized. Clinical trials evaluating immune checkpoint inhibitors (ICIs) in UM have demonstrated response rates lower than those seen in cutaneous melanoma. Despite lower efficacy demonstrated in initial ICI studies, there are a number of ongoing clinical trials investigating novel immunotherapy approaches in UM. SUMMARY: This review aims to summarize important ongoing clinical trials investigating immunotherapeutic approaches in UM and previous trials that have evaluated a number of immunologic interventions. A thorough clinical trial investigation was conducted through clinicaltrials.gov using the disease search terms "uveal melanoma" and "ocular melanoma," excluding non-immunotherapy-related trials. Here, we report on ICI, vaccine, adoptive T cells, and combination immunotherapy trials in UM. KEY MESSAGES: There is an increasing effort in the search for new, effective therapies for this difficult-to-treat disease, with immunotherapeutic approaches being of particular interest. Increasing knowledge of UM biology and development of new biomarkers will direct future drug development and trial design.
Authors: Ajay V Maker; Giao Q Phan; Peter Attia; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Leah R Haworth; Catherine Levy; David Kleiner; Sharon A Mavroukakis; Michael Yellin; Steven A Rosenberg Journal: Ann Surg Oncol Date: 2005-10-21 Impact factor: 5.344
Authors: Alain P Algazi; Katy K Tsai; Alexander N Shoushtari; Rodrigo R Munhoz; Zeynep Eroglu; Josep M Piulats; Patrick A Ott; Douglas B Johnson; Jimmy Hwang; Adil I Daud; Jeffrey A Sosman; Richard D Carvajal; Bartosz Chmielowski; Michael A Postow; Jeffrey S Weber; Ryan J Sullivan Journal: Cancer Date: 2016-08-17 Impact factor: 6.860
Authors: Jedd D Wolchok; Vanna Chiarion-Sileni; Rene Gonzalez; Piotr Rutkowski; Jean-Jacques Grob; C Lance Cowey; Christopher D Lao; John Wagstaff; Dirk Schadendorf; Pier F Ferrucci; Michael Smylie; Reinhard Dummer; Andrew Hill; David Hogg; John Haanen; Matteo S Carlino; Oliver Bechter; Michele Maio; Ivan Marquez-Rodas; Massimo Guidoboni; Grant McArthur; Celeste Lebbé; Paolo A Ascierto; Georgina V Long; Jonathan Cebon; Jeffrey Sosman; Michael A Postow; Margaret K Callahan; Dana Walker; Linda Rollin; Rafia Bhore; F Stephen Hodi; James Larkin Journal: N Engl J Med Date: 2017-09-11 Impact factor: 91.245
Authors: Markus V Heppt; Theresa Steeb; Justin Gabriel Schlager; Stefanie Rosumeck; Corinna Dressler; Thomas Ruzicka; Alexander Nast; Carola Berking Journal: Cancer Treat Rev Date: 2017-08-24 Impact factor: 12.111
Authors: Charlotte Pandiani; Guillaume E Béranger; Justine Leclerc; Robert Ballotti; Corine Bertolotto Journal: Genes Dev Date: 2017-04-15 Impact factor: 11.361
Authors: Caroline Boudousquie; Giovanna Bossi; Jacob M Hurst; Karolina A Rygiel; Bent K Jakobsen; Namir J Hassan Journal: Immunology Date: 2017-08-02 Impact factor: 7.397
Authors: Markus V Heppt; Teresa Amaral; Katharina C Kähler; Lucie Heinzerling; Jessica C Hassel; Markus Meissner; Nicole Kreuzberg; Carmen Loquai; Lydia Reinhardt; Jochen Utikal; Evelyn Dabrowski; Anja Gesierich; Claudia Pföhler; Patrick Terheyden; Kai-Martin Thoms; Lisa Zimmer; Thomas K Eigentler; Michael C Kirchberger; Henner M Stege; Friedegund Meier; Max Schlaak; Carola Berking Journal: J Immunother Cancer Date: 2019-11-13 Impact factor: 13.751
Authors: Lukas Kraehenbuehl; Aliya Holland; Emma Armstrong; Sirinya O'Shea; Levi Mangarin; Sara Chekalil; Amanda Johnston; John S Bomalaski; Joseph P Erinjeri; Christopher A Barker; Jasmine H Francis; Jedd D Wolchok; Taha Merghoub; Alexander N Shoushtari Journal: Cancers (Basel) Date: 2022-05-26 Impact factor: 6.575